Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1204-1208

  Leung, Sing F ^a   Chan, K C A ^a   Ma, B B ^a   Hui, E P ^a   Mo, F ^a   Chow, K C K ^a   Leung, L ^a   Chu, K W ^a   Zee, B ^a   Lo, Y M D ^a   Chan, A T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carcinoma; DNA; EBV; Nasopharyngeal

Indexed keywords

CISPLATIN; TUMOR MARKER; VIRUS DNA;

ARTICLE; BRACHYTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; VIRUS LOAD; BLOOD; COMPLICATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIROLOGY;

CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD;

EID: 84903515220     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu117     Document Type: Article

References (19)

1. Lo YM, Chan LY, Lo KW et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 00:00 1188-1191.
2. Lo YM, Leung SF, Chan LY et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60: 2351-2355.
3. Shotelersuk K, Khorprasert C, Sakdikul S et al. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000; 6: 1046-1051.
4. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-1619.
5. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.
6. Le QT, Jones CD, Yau TK et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 2005; 11: 5700-5707.
7. Lin JC, Wang WY, Liang WM et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1342-1348.
8. Langendijk JA, Leemans CR, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22: 4604-4612.
9. Baujat B, Audry H, Bourhis J et al. MAC-NPC Collaborative Group. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev 2006; 4: CD004329.
10. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 1998; 16: 1310-1317.
11. Chen L, Hu CS, Chen XZ et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13: 163-171.
12. Lee NY, Zhang Q, Pfister DG et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012; 13: 172-180.
13. Ma BB, Kam MK, Leung SF et al. A phase II study of concurrent cetuximabcisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23: 1287-1292.
14. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 5th edition. New York: Wiley-Liss. 1997; 26-32.
15. Leung SF, Zee B, Ma BB et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements TNM staging in nasopharyngeal carcinoma prognostication. J Clin Oncol 2006; 24: 5414-5418.
16. Zhao L, Wan Q, Zhou Y et al. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 2011; 98: 23-27.
17. Mazumdar M, Bajorin DF, Bacik J et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-2541.
18. Wang WY, Twu CW, Chen HH et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16: 1016-1024.
19. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.